Navigation Links
SyntheMed Receives Canadian Approval for REPEL-CV(R)
Date:7/14/2008

ISELIN, N.J., July 14 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that REPEL-CV(R), the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery. REPEL-CV will be marketed throughout Canada by Force3 Medicale, Inc., a Montreal-based distributor of cardiac surgery products. Marc Sportsman, SyntheMed's Vice President of Sales, stated, "We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of REPEL-CV."

SyntheMed was previously granted CE Mark approval to market REPEL-CV in most international markets for use in all patients who undergo open heart surgery and is being sold through a network of independent distributors. In November 2007, SyntheMed received an Approval Letter from the US FDA stating the REPEL-CV would be approved for use in pediatric patients pending satisfactory completion of field inspections. This process is ongoing as are discussions with the FDA on the requirements for expansion of the indication for REPEL-CV from pediatric patients to all patients who undergo cardiac surgery.

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of ... Chief Scientific Officer, will present at the Stem Cell ... Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining ... , Senior citizens can qualify for affordable term life ... who are over 50 years old. Some term life ... examination. , Term life insurance with a simplified issue ... Having life insurance during retirement is important for covering ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay News) ... might have another use: clearing arterial blockages in the ... research involving 19 stroke patients, doctors say this experimental ... patients for whom other clot-removal methods didn,t work. ...
... health may contribute to a healthy respiratory system, according ... . A new study suggests that periodontal disease may ... obstructive pulmonary disease (COPD) and pneumonia. These infections, which ... inhaled into the lower respiratory tract, can be severely ...
... advise about alcohol consumption?" was recently published by Maurizio Ponz ... argues that the message of health benefits of moderate drinking ... the general population." His reasons included (1) many people ... of wine, beer or spirits, and alcohol metabolism may differ ...
... 18 (HealthDay News) -- Women with polycystic ovary syndrome (PCOS) ... many consumer products than other women, a new study suggests. ... products, food and drink packaging and even dental materials. PCOS, ... characterized by excessive production of male sex hormones (androgens). PCOS ...
... XX, 2010) Thea Friedman, M.D., associate scientist and ... Cancer Center at Hackensack University Medical Center was recently ... (NIH-NCI) RO1 research grant to improve allogeneic blood ... grant provides $2 million in funding over the next ...
... is available in French . Montreal, ... in biology at Universit du Qubec Montral (UQAM), supported ... Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED ... B-cell acute lymphocytic leukemia, a disease that occurs most commonly ...
Cached Medicine News:Health News:Stents Show Promise in Treating Brain Blockages 2Health News:Stents Show Promise in Treating Brain Blockages 3Health News:Healthy gums may lead to healthy lungs 2Health News:Critique 029: What should we advise about alcohol consumption? A debate amongst scientists 2Health News:Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical 2Health News:Oncology basic research director at John Theurer Cancer Center continues transplantation research 2Health News:Discovery of a gene associated with a leukemia mostly affecting children 2
Rees bayonet forceps, standard, 5-1/2", TC....
... Channel Implants, designed to accept ... surgeon with an excellent reconstructive ... and floor blowout defects. Each ... placement of one or more ...
Medpor Complete Orbit are designed to replace non load bearing bony structures in the orbital area....
... Medpor Inferior Orbital Rim implant can provide ... is designed to be trimmed to meet ... small flange allows it to rest on ... floor. This flange allows easier positioning of ...
Medicine Products: